This phase I trial is testing a new oral drug in patients with advanced cancers (excluding some types of blood cancer).
This trial is treating patients with advanced solid cancers (excluding some types of blood cancer).
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor
Maxinovel Pty., Ltd.
This is a dose escalation and expansion study, in which eligible patients will receive oral MAX-10181 once or twice a day, with dose modifications based on set tolerability criteria. In part two of the study, eligible participants will receive oral MAX-10181 at a recommended dose, based on the outcomes of study part one.
Recruiting Hospitals Read More